Skip to search formSkip to main contentSkip to account menu

PAI 039

Known as: PAI-039, PAI039 cpd 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tiplaxtinin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Plasminogen activator inhibitor‐1 augments damage by impairing fibrinolysis after traumatic brain injury
Plasminogen activator inhibitor‐1 (PAI‐1) is the key endogenous inhibitor of fibrinolysis, and enhances clot formation after… 
2018
2018
PAI-1 Exacerbates White Adipose Tissue Dysfunction and Metabolic Dysregulation in High Fat Diet-Induced Obesity
Background: Plasminogen activator inhibitor (PAI)-1 levels and activity are known to increase during metabolic syndrome and… 
2015
2015
Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma
BackgroundAn increased incidence of venous thromboembolism (VTE) is associated with anti-vascular endothelial growth factor (VEGF… 
2012
2012
Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase…
Spatial and temporal regulation of the pericellular proteolytic environment by local growth factors, such as EGF and TGF… 
Highly Cited
2012
Highly Cited
2012
Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.
BACKGROUND Plasminogen activator inhibitor-1 (PAI-1) is a protease inhibitor but is paradoxically associated with poor outcomes… 
Highly Cited
2008
Highly Cited
2008
Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis
Summary.  Objective: To assess the antithrombotic and profibrinolytic effects of tiplaxtinin (PAI‐039), an orally bioavailable… 
2008
2008
Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis
Summary This study aimed to evaluate a small-molecule PAI-1 inhibitor (PAI-039; tiplaxtinin) in a rodent stenosis model of venous… 
Highly Cited
2006
Highly Cited
2006
Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1
Objective—The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was… 
Highly Cited
2006
Highly Cited
2006
Effect of pharmacologic plasminogen activator inhibitor‐1 inhibition on cell motility and tumor angiogenesis
Summary.  Background: Plasminogen activator inhibitor‐1 (PAI‐1) is integrally involved in tumorigenesis by impacting on both… 
2005
2005
Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis
We tested a novel, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) in a canine model of electrolytic injury… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)